Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
difficulty in enrollment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To observe the decreased levels of low-density lipoprotein from baseline in patients with obesity-related glomerulopathy (ORG) after 12 weeks of Sevelamer Carbonate treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A Group | Experimental |
| |
| B Group | Experimental |
| |
| C Group | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| High dosage Sevelamer Carbonate + Irbesartan | Drug | Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d |
|
| Measure | Description | Time Frame |
|---|---|---|
| low-density lipoprotein | decreased levels of low-density lipoprotein from baseline | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| uric acid | Changes of uric acid from baseline after 12 weeks of treatment | 12 weeks |
| blood lipids parameters (CHO, TG, HDL) | Changes of blood lipids parameters from baseline after 12 weeks of treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine | Nanjing | Jiangsu | 210002 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Low dosage Sevelamer Carbonate + Irbesartan | Drug | Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d |
|
| Irbesartan | Drug | Irbesartan 300mg/d |
|
| 12 weeks |
| proteinuria | Changes of proteinuria from baseline after 12 weeks of treatment | 12 weeks |
| blood glucose | Changes of blood glucose from baseline after 12 weeks of treatment | 12 weeks |
| glycated hemoglobin | Changes of glycated hemoglobin from baseline after 12 weeks of treatment | 12 weeks |
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077405 | Irbesartan |
| ID | Term |
|---|---|
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D013141 | Spiro Compounds |
| D013777 | Tetrazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided